查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2103683

胃麻痺治療市場：全球市場預測，2026-2032年

Gastroparesis Drugs Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，胃麻痺治療市場規模將成長至 79.7 億美元，複合年成長率為 7.27%。

主要市場統計數據
基準年 2025 48.7億美元
預計年份：2026年 52.4億美元
預測年份 2032 79.7億美元
複合年成長率 (%) 7.27%

胃麻痺治療藥物執行摘要

胃麻痺藥物用於治療慢性胃動力障礙，其特徵是胃內容物排空延遲，即使不存在機械性梗阻，也會導致噁心、嘔吐、早飽、腹脹、腹痛、營養不良風險、血糖控制不佳、反覆就診。此治療領域存在大量未滿足的需求，尤其是在糖尿病患者、術後併發症患者、特發性疾病患者、神經系統疾病患者以及藥物相關性胃動力障礙患者。目前的藥物治療依賴胃動力增強劑、止吐藥、神經調節劑和營養支持策略來控制症狀，但臨床研發正日益關注改善胃適應性、幽門收縮力、幽門功能和噁心路徑等標靶機制。胃麻痺藥物產業的主要主題包括糖尿病性胃麻痺的治療、特發性胃麻痺的治療、胃動力增強劑、止吐藥、經腸營養支持以及新型消化器官系統藥物的研發。由於目前一些療法面臨許多挑戰，例如神經系統副作用、心臟安全監測、使用時長限制、症狀反應個體差異以及仿單標示外用藥等，因此對更安全、更持久的治療方案的需求依然強勁。

胃麻痺治療市場的變革性變化

在胃麻痺治療領域，正在發生結構性轉變，從廣泛的症狀抑制轉向基於作用機制的患者導向型治療。由於潛在的病理生理機制和治療反應可能存在顯著差異，臨床實踐中越來越傾向於區分糖尿病、特發性、術後、神經系統和藥物引起的胃排空延遲。胃排空閃爍顯像、呼吸檢測、無線運動功能膠囊（如有）和標準化症狀評分的日益普及，提高了診斷的一致性和患者分層能力。另一個顯著的變化是人們對藥物引起的胃排空延遲的認知不斷提高，尤其是在糖尿病和肥胖症治療中廣泛應用腸促胰素代謝療法的情況下。這凸顯了藥物評估、風險分層以及胃腸病學、內分泌學、營養學和基層醫療等學科之間協作的必要性。在治療研發方面，藥物研發正從傳統的多巴胺拮抗劑和大環內酯類藥物轉向靶向生長素釋放Ghrelin受體、血清素通路、神經激肽介導的噁心、幽門功能障礙以及中樞和外周腸腦訊號傳導的藥物。監管機構仍然優先考慮具有臨床意義的症狀改善、檢驗的患者報告結局、長期安全性以及在不同患者群體中的循證醫學證據。這些變化共同提高了胃麻痺治療創新的標準，並促進了更全面的醫療模式的形成。

人工智慧對胃麻痺藥物的累積影響

人工智慧 (AI) 對胃麻痺藥物研發、臨床試驗設計、診斷支援和真實世界數據 (REW) 產生的影響日益顯著。在藥物研發階段，AI 驅動的篩檢和分子建模能夠在早期開發階段識別影響胃動力路徑、受體選擇性、噁心訊號傳導和安全性風險的化合物。在臨床實踐中，機器學習可用於整合症狀模式、胃排空結果、糖尿病狀況、用藥史、自主神經神經病變指標、營養狀況指標和既往治療反應等信息，以幫助篩選符合條件的患者。鑑於胃麻痺生物學特徵的變異性和症狀嚴重程度的波動性，這一點在胃麻痺症臨床試驗中尤其重要。在醫療保健領域，AI 驅動的分析有助於識別存在診斷延遲、脫水、營養不良、急診就診或藥物引起的胃排空功能惡化風險的患者。對醫療記錄進行自然語言處理有助於識別編碼不規範的病例，而遠端監測工具可以捕捉嘔吐頻率、口服攝入量、血糖波動、體重變化以及患者自述結局（PRO）。然而，將人工智慧引入胃麻痺治療必須解決數據品質、代表性、臨床有效性、可解釋性、隱私合規性和偏差緩解等挑戰。這些努力結合起來，將創建一個主導生態系統，使製藥公司、臨床醫生和保險公司能夠更準確地將治療機制與可衡量的患者結局聯繫起來。

關於引入胃麻痺藥物的關鍵區域見解

在亞太地區，糖尿病盛行率的上升、胃腸病專科服務的擴展以及診斷檢測的可及性提高，促使人們更加關注糖尿病性胃麻痺的治療和胃動力障礙的管理。中國、印度、日本、韓國和澳洲是臨床能力、數位醫療應用和監管活動的重要中心。北美憑藉其先進的診斷基礎設施、完善的專科診療路徑、積極參與臨床研究以及對治療局限性（尤其是在長期使用胃動力增強劑和止吐藥方面）的日益重視，仍然具有重要影響力。拉丁美洲的特徵是都市區胃腸病服務的可及性有所提高，一些國家糖尿病負擔沉重，以及對價格合理的對症治療的需求日益成長，儘管胃排空診斷和轉診專科醫生方面的差異仍然是主要障礙。在歐洲，重點是指南導向的醫療、藥物安全監測和安全監控，國家醫療保健系統支持對糖尿病併發症、功能性胃腸疾病和胃腸動力障礙採取系統性的方法。在中東，與糖尿病和肥胖相關的代謝性疾病仍然是重要的公共衛生問題，胃麻痺治療的重要性日益凸顯，尤其是在海灣國家，那裡的三級醫療網路和專科診所正在不斷擴展。在非洲，雖然人們對糖尿病的認知不斷提高，但情況仍在發展中且不均衡，胃排空檢查、專業的胃動力護理、經腸營養支持和先進藥物療法的可及性有限。因此，非洲迫切需要可擴展的診斷系統、基本藥物以及切實可行的診療路徑。

胃麻痺藥物的主要群體分析

在東南亞國協，由於糖尿病照護的擴展和都市區醫療系統胃腸道診斷能力的提高，獲得胃麻痺治療變得日益重要，儘管各成員國之間的成本效益、報銷範圍和專科醫生資源存在差異。海灣合作理事會（GCC）國家由於糖尿病盛行率高、對先進醫院的投資以及不斷擴大的專科醫療服務，成為具有戰略意義的關鍵市場，這導致人們對糖尿病性胃麻痺的認知不斷提高，對相關藥物治療的需求也日益成長。歐盟（EU）的法規環境十分嚴格，藥物安全、上市後監測、統一證據標準和醫療技術評估都會影響胃麻痺治療和長期用藥的可近性。金磚國家（BRICS）擁有大規模的患者群體、日益沉重的代謝性疾病負擔、不斷擴展的國家臨床研究體係以及多樣化的報銷機制。因此，證據的產生、成本效益以及遵守當地法規至關重要。七國集團通常是先進胃腸病學研究、檢驗的臨床終點、藥物安全監測系統和保險公司審查的基礎，這些因素共同塑造了全球對胃麻痺治療的療效、安全性和患者報告結局的預期。北約成員國的醫療保健系統與北美和高所得歐洲國家的醫療保健系統高度重合，在這些國家，健全的藥品供應鏈、監管間的協調、醫院的響應能力以及獲得專科治療的機會仍然是慢性胃腸動力障礙管理的關鍵考慮因素。

對胃麻痺治療需求的關鍵國家洞察。

在美國，胃麻痺的醫療保健體系已經相當完善，這得益於專業的運動中心、廣泛的臨床試驗活動以及公眾對糖尿病性和特發性胃麻痺症的高度認知。然而，長期使用運動促進藥物的安全性問題仍影響著處方決策。在加拿大，循證治療、省級醫療保健系統的覆蓋以及轉診途徑都得到了重視，但仍需改善及時診斷和確保各地區醫療資源的公平獲取。在墨西哥和巴西，與糖尿病相關的醫療保健需求極高，因此，降低胃麻痺症狀的治療成本、改善診斷途徑以及加強醫護人員的教育是重中之重。英國、德國、法國、義大利和西班牙體現了歐洲成熟的醫療保健體系，胃腸病學指南、藥物安全監測和保險報銷審查等因素影響著促動力藥、止吐藥和新興療法的應用。在俄羅斯，雖然需要治療的患者數量龐大，但各地區獲得專業診斷基礎設施的機會卻不盡相同。由於中國和印度糖尿病患者數量龐大、醫院網路不斷擴展，且對消化器官系統藥物的需求日益成長，預計兩國將在未來疾病認知方面發揮核心作用，儘管都市區醫療資源獲取方面的差距仍然是一項重大挑戰。日本在功能性胃腸疾病和胃動力障礙的研究方面擁有長期累積的專業知識，為基於症狀的治療和安全性監測提供了先進的臨床支持。澳洲受益於完善的專科醫療保健體系和基於指南的管理，而韓國憑藉其先進的醫院系統、數位醫療的普及以及對胃腸道創新的積極投入，是胃麻痺和胃腸動力障礙治療領域的重要國家。

為胃麻痺治療領域的領導企業提供實用建議

產業領導企業應優先考慮能夠明確區分糖尿病、特發性、術後、神經系統疾病和藥物相關性胃排空延遲的研發項目。區分患者群體有助於最佳化終點選擇和治療定位。臨床試驗應結合客觀的胃排空指標、檢驗的症狀評分、營養相關結局、急救藥物使用、相關血糖控制指標以及生活品質 (QOL) 指標，來證明治療的顯著益處。安全性策略至關重要，尤其對於長期用藥的療法而言，應根據需要進行神經系統、心血管、代謝和藥物交互作用監測。各機構應投資於與胃腸病學、內分泌學和營養學網路開展真實世界證據 (REW) 合作，以更深入地了解治療途徑、治療中斷因素、急診醫療利用情況以及患者報告的疾病負擔。數位化工具可以增強藥物依從性追蹤、症狀日記、脫水警報、飲食監測和遠端隨訪，但這些工具必須經過臨床檢驗，並且設計得便於患者使用。市場准入計畫應著重關注未被滿足的需求、減少急診的使用、穩定營養狀況以及長期管理的適用性，而非依賴寬泛的、針對症狀的療效主張。教育舉措應幫助臨床醫生早期識別胃麻痺，評估藥物引起的胃排空延遲，並協調多學科治療。

研究實證胃麻痺治療方法的調查方法

本執行摘要基於公開檢驗的資訊來源，包括同行評審的醫學文獻、臨床實踐指南、監管安全資訊、臨床試驗註冊資訊、疾病負擔出版物和醫療保健政策參​​考資料，透過二手研究和證據整合編寫而成。調查方法優先考慮以數據為導向，解讀疾病流行病學因素、診斷標準、治療機制、臨床未滿足需求、安全性考量、區域醫療保健服務取得模式以及影響胃麻痺治療的監管因素。為確保研究結果的一致性並避免未經證實的結論，研究結果已在胃腸病學、內分泌學、藥理學、臨床營養學和醫療保健系統等資訊來源進行了交叉檢驗。本分析有意排除市場規模估算、市場佔有率計算和預測，而是著重於定性產業洞察、治療格局評估和實證策略啟示。透過將胃麻痺與糖尿病負擔、診斷基礎設施、專家的可用性、藥物可及性、監管成熟度、對藥物安全監測的期望以及醫療保健系統接受這些因素的能力等因素進行關聯，得出了區域、群體和國家層面的具體見解。

結論

胃腸麻痺的治療仍是胃腸病學領域亟待創新的關鍵方向。這是因為目前的治療方案往往無法充分緩解症狀，並且可能受到安全性、耐受性和使用時間長度的限制。最大的機會在於開發能夠明確解決胃排空延遲和噁心機制，同時又能持續改善症狀、長期使用安全性良好且療效可衡量（以患者為中心）的療法。糖尿病照護的區域性擴展、診斷意識的提高以及專科醫療服務的加強，都提高了成熟和新興醫療體系對胃排空延遲的認知。人工智慧、真實世界數據和數位症狀監測，如果能夠合理應用，有望提高患者識別率、簡化臨床試驗流程並加強治療後評估。將嚴格的臨床證據、差異化的患者細分、以安全為中心的開發和可操作的准入策略結合起來的相關人員，將最有能力滿足糖尿病胃腸麻痺、特發性胃腸麻痺和更廣泛的胃動力障礙治療中尚未滿足的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：胃麻痺治療藥物市場：依藥物類型分類

  • 多巴胺拮抗劑
    • 西沙必利
    • 多姆哌立登
    • 甲氧氯普胺
  • 胃動素受體促效劑
    • 阿奇黴素
    • 紅黴素
  • 血清素受體促效劑
    • Granisetron
    • Ondansetron

第8章：胃麻痺治療市場：依疾病類型分類

  • 糖尿病性胃輕癱
  • 特發性胃麻痺
  • 術後胃輕癱

第9章：胃麻痺治療藥物市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 經皮給藥

第10章：胃麻痺治療藥物市場：依最終用戶分類

  • 診所
  • 居家醫療
  • 醫院

第11章：胃麻痺治療藥物市場：依分銷管道分類

  • 離線
  • 線上

第12章：胃麻痺治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：胃麻痺治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：胃麻痺治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Amneal Pharmaceuticals, Inc.
  • ANI Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Atlantic Healthcare PLC
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Limited
  • Cairn Diagnostics
  • Evoke Pharma, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin International plc
  • Lupin Limited
  • Medtronic PLC
  • Neurogastrx, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Processa Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Theravance Biopharma
  • Vanda Pharmaceuticals Inc.
  • Viatris Inc.
Product Code: MRR-C002B1C996F5

The Gastroparesis Drugs Market is projected to grow by USD 7.97 billion at a CAGR of 7.27% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.87 billion
Estimated Year [2026] USD 5.24 billion
Forecast Year [2032] USD 7.97 billion
CAGR (%) 7.27%

Gastroparesis Drugs Executive Summary

Gastroparesis drugs address a chronic gastric motility disorder in which delayed gastric emptying occurs without mechanical obstruction, leading to nausea, vomiting, early satiety, bloating, abdominal pain, malnutrition risk, impaired glycemic control, and repeated healthcare utilization. The therapeutic landscape is shaped by high unmet need, particularly among people with diabetes, post-surgical complications, idiopathic disease, neurologic conditions, and medication-associated gastric dysmotility. Current pharmacologic management relies on prokinetic agents, antiemetics, neuromodulators used for symptom control, and supportive nutritional strategies, while clinical development increasingly focuses on targeted mechanisms that improve gastric accommodation, antral contractility, pyloric function, and nausea pathways. The themes defining the gastroparesis drugs industry include diabetic gastroparesis treatment, idiopathic gastroparesis therapy, prokinetic drugs, antiemetic treatment, gastric motility therapeutics, enteral nutrition support, and novel gastroenterology drug development. Demand for safer long-term therapies remains strong because several available treatments carry limitations related to neurological adverse effects, cardiac safety monitoring, restricted duration of use, variable symptom response, and off-label prescribing practices.

Transformative Shifts in the Gastroparesis Drugs Landscape

The gastroparesis drugs landscape is undergoing a structural shift from broad symptom suppression toward mechanism-informed, patient-segmented therapy. Clinical practice is increasingly differentiating diabetic, idiopathic, post-surgical, neurologic, and medication-induced gastroparesis because underlying pathophysiology and treatment response can differ substantially. Wider use of gastric emptying scintigraphy, breath testing, wireless motility capsule assessment where available, and standardized symptom scoring is improving diagnostic consistency and patient stratification. Another major shift is the growing recognition of drug-induced delayed gastric emptying, especially as incretin-based metabolic therapies become more widely used for diabetes and obesity management; this is increasing the need for medication review, risk stratification, and coordinated care between gastroenterology, endocrinology, nutrition, and primary care. Therapeutic development is also moving beyond traditional dopamine antagonist and macrolide approaches toward agents targeting ghrelin receptors, serotonin pathways, neurokinin-mediated nausea, pyloric dysfunction, and central-peripheral gut-brain signaling. Regulatory expectations continue to emphasize clinically meaningful symptom improvement, validated patient-reported outcomes, safety in chronic use, and evidence across heterogeneous patient populations. Together, these shifts are raising the bar for gastroparesis drug innovation and supporting more integrated care models.

Cumulative Impact of Artificial Intelligence on Gastroparesis Drugs

Artificial intelligence is increasingly influencing gastroparesis drug discovery, clinical trial design, diagnosis support, and real-world evidence generation. In discovery, AI-enabled screening and molecular modeling can help identify compounds affecting motility pathways, receptor selectivity, nausea signaling, and safety liabilities earlier in development. In clinical operations, machine learning can support patient enrichment by integrating symptom patterns, gastric emptying results, diabetes status, medication history, autonomic neuropathy indicators, nutritional markers, and prior treatment response. This is particularly relevant because gastroparesis trials often face heterogeneous disease biology and fluctuating symptom severity. In care delivery, AI-assisted analytics can help flag patients at risk of delayed diagnosis, dehydration, malnutrition, emergency visits, or medication-related worsening of gastric emptying. Natural language processing of clinical notes may improve identification of under-coded cases, while remote monitoring tools can capture vomiting frequency, oral intake, glucose variability, weight change, and patient-reported outcomes. However, AI adoption in gastroparesis drugs must address data quality, representativeness, clinical validation, explainability, privacy compliance, and bias mitigation. The cumulative impact is a more evidence-driven ecosystem in which drug developers, clinicians, and payers can better connect therapeutic mechanisms with measurable patient outcomes.

Key Regional Insights Across Gastroparesis Drug Adoption

In Asia-Pacific, rising diabetes prevalence, expanding specialist gastroenterology services, and growing access to diagnostic testing are increasing attention to diabetic gastroparesis drugs and motility disorder management, with China, India, Japan, South Korea, and Australia serving as important centers for clinical capability, digital health adoption, and regulatory activity. North America remains highly influential because of advanced diagnostic infrastructure, established specialty care pathways, active clinical research participation, and heightened awareness of treatment limitations, particularly in chronic prokinetic and antiemetic use. Latin America is characterized by improving access to gastroenterology services in urban centers, a high burden of diabetes in several countries, and growing need for affordable symptomatic management, although disparities in gastric emptying diagnostics and specialist referral remain key barriers. Europe emphasizes guideline-driven care, pharmacovigilance, and safety monitoring, with national health systems supporting structured approaches to diabetic complications, functional gastrointestinal disorders, and gastrointestinal motility disorders. The Middle East is seeing increasing relevance of gastroparesis therapeutics as diabetes and obesity-related metabolic disease remain prominent public health priorities, especially in Gulf economies with expanding tertiary care networks and specialty clinics. Africa presents an emerging but uneven landscape where diabetes recognition is increasing, yet access to gastric emptying diagnostics, specialist motility services, enteral nutrition support, and advanced pharmacologic options can be limited, creating demand for scalable diagnosis, essential medication access, and practical care pathways.

Key Group Insights for Gastroparesis Drugs

ASEAN countries are becoming more relevant to gastroparesis drug access as diabetes care expands and urban healthcare systems improve gastrointestinal diagnostic capacity, though affordability, reimbursement depth, and specialist availability vary across member states. The GCC demonstrates strong strategic relevance because high diabetes prevalence, investment in advanced hospitals, and expanding specialty care support greater recognition of diabetic gastroparesis and related pharmacologic needs. The European Union offers a highly regulated environment in which drug safety, post-marketing surveillance, harmonized evidence standards, and health technology assessment influence access to gastroparesis therapies and chronic-use medications. BRICS economies bring together large patient populations, rising metabolic disease burden, expanding domestic clinical research ecosystems, and variable reimbursement structures, making evidence generation, cost-effectiveness, and local regulatory alignment essential. G7 countries typically anchor advanced gastroenterology research, validated clinical endpoints, pharmacovigilance systems, and payer scrutiny, which together shape global expectations for gastroparesis drug efficacy, safety, and patient-reported outcomes. NATO member countries overlap substantially with high-income healthcare systems in North America and Europe, where secure pharmaceutical supply chains, regulatory coordination, hospital readiness, and specialty treatment access remain important considerations for chronic gastrointestinal motility disorder management.

Key Country Insights in Gastroparesis Drug Demand

The United States has a well-developed gastroparesis care environment supported by specialist motility centers, broad clinical trial activity, and strong awareness of diabetic and idiopathic gastroparesis, while safety concerns around long-term prokinetic use continue to shape prescribing decisions. Canada emphasizes evidence-based treatment, access through provincial systems, and specialist referral pathways, with ongoing need to improve timely diagnosis and equitable access across geographies. Mexico and Brazil face substantial diabetes-related care needs, making affordable gastroparesis symptom management, improved diagnostic access, and clinician education important priorities. The United Kingdom, Germany, France, Italy, and Spain reflect mature European care settings where gastroenterology guidelines, medicine safety oversight, and reimbursement review influence the adoption of prokinetics, antiemetics, and emerging therapies. Russia presents a large treatment population with variable access to specialized diagnostic infrastructure across regions. China and India are central to future disease recognition because of large diabetes populations, expanding hospital networks, and growing demand for gastrointestinal therapeutics, although rural-urban access gaps remain important. Japan has long-standing expertise in functional gastrointestinal disorders and gastric motility research, supporting sophisticated clinical understanding of symptom-based treatment and safety monitoring. Australia benefits from strong specialist care and guideline-oriented management, while South Korea combines advanced hospital systems, digital health adoption, and active interest in gastrointestinal innovation, making it an important country for gastroparesis drugs and motility-focused therapeutics.

Actionable Recommendations for Gastroparesis Drug Leaders

Industry leaders should prioritize development programs that clearly distinguish diabetic, idiopathic, post-surgical, neurologic, and medication-associated gastroparesis because differentiated patient populations can improve endpoint selection and therapeutic positioning. Clinical trials should combine objective measures of gastric emptying with validated symptom scores, nutrition-related outcomes, rescue medication use, glycemic control markers where relevant, and quality-of-life measures to demonstrate meaningful benefit. Safety strategy is critical, particularly for therapies intended for chronic use, and should include neurological, cardiovascular, metabolic, and drug-interaction monitoring where relevant. Organizations should invest in real-world evidence partnerships with gastroenterology, endocrinology, and nutrition networks to better understand treatment pathways, discontinuation drivers, emergency care utilization, and patient-reported disease burden. Digital tools can strengthen adherence tracking, symptom diaries, dehydration alerts, dietary monitoring, and remote follow-up, but should be clinically validated and designed for patient usability. Market access planning should focus on unmet need, reduction in acute care utilization, nutritional stabilization, and suitability for long-term management rather than relying on broad symptomatic claims. Education initiatives should help clinicians recognize gastroparesis earlier, assess medication-induced delayed emptying, and coordinate multidisciplinary treatment.

Research Methodology for Evidence-Based Gastroparesis Drug Insights

This executive summary is developed through secondary research and evidence synthesis using publicly available, verifiable sources such as peer-reviewed medical literature, clinical practice guidelines, regulatory safety communications, clinical trial registries, disease burden publications, and healthcare policy references. The methodology prioritizes data-backed interpretation of disease epidemiology drivers, diagnostic standards, therapeutic mechanisms, clinical unmet needs, safety considerations, regional healthcare access patterns, and regulatory factors affecting gastroparesis drugs. Insights were cross-checked across gastroenterology, endocrinology, pharmacology, clinical nutrition, and health systems sources to maintain consistency and avoid unsupported claims. The analysis deliberately excludes market estimation, market sizing, market share calculation, and forecasting, focusing instead on qualitative industry intelligence, treatment landscape assessment, and evidence-based strategic implications. Regional, group, and country insights were developed by mapping gastroparesis relevance to diabetes burden, diagnostic infrastructure, specialist availability, medicine access, regulatory maturity, pharmacovigilance expectations, and healthcare system capacity.

Conclusion

Gastroparesis drugs remain an important area of gastroenterology innovation because current treatment options often provide incomplete relief and can be constrained by safety, tolerability, and duration-of-use limitations. The strongest opportunities lie in therapies that address defined mechanisms of delayed gastric emptying and nausea while demonstrating durable symptom improvement, acceptable chronic-use safety, and measurable patient-centered outcomes. Regional growth in diabetes care, improved diagnostic awareness, and expanding specialty services are increasing recognition of gastroparesis across both mature and emerging healthcare systems. Artificial intelligence, real-world evidence, and digital symptom monitoring are likely to strengthen patient identification, trial efficiency, and post-treatment assessment when implemented responsibly. Industry stakeholders that combine rigorous clinical evidence, differentiated patient segmentation, safety-focused development, and practical access strategies will be best positioned to meet unmet needs in diabetic gastroparesis, idiopathic gastroparesis, and broader gastric motility disorder treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Gastroparesis Drugs Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Dopamine Antagonists
    • 7.2.1. Cisapride
    • 7.2.2. Domperidone
    • 7.2.3. Metoclopramide
  • 7.3. Motilin Receptor Agonists
    • 7.3.1. Azithromycin
    • 7.3.2. Erythromycin
  • 7.4. Serotonin Receptor Agonists
    • 7.4.1. Granisetron
    • 7.4.2. Ondansetron

8. Gastroparesis Drugs Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Diabetic Gastroparesis
  • 8.3. Idiopathic Gastroparesis
  • 8.4. Postsurgical Gastroparesis

9. Gastroparesis Drugs Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Injectable
  • 9.3. Oral
  • 9.4. Transdermal

10. Gastroparesis Drugs Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Home Care Settings
  • 10.4. Hospitals

11. Gastroparesis Drugs Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Offline
  • 11.3. Online

12. Gastroparesis Drugs Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Gastroparesis Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Gastroparesis Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. AbbVie Inc.
  • 16.3. Amneal Pharmaceuticals, Inc.
  • 16.4. ANI Pharmaceuticals, Inc.
  • 16.5. AstraZeneca PLC
  • 16.6. Atlantic Healthcare PLC
  • 16.7. Bausch Health Companies Inc.
  • 16.8. Bristol-Myers Squibb Company
  • 16.9. Cadila Pharmaceuticals Limited
  • 16.10. Cairn Diagnostics
  • 16.11. Evoke Pharma, Inc.
  • 16.12. GlaxoSmithKline PLC
  • 16.13. Johnson & Johnson Services, Inc.
  • 16.14. Kyowa Kirin International plc
  • 16.15. Lupin Limited
  • 16.16. Medtronic PLC
  • 16.17. Neurogastrx, Inc.
  • 16.18. Novartis AG
  • 16.19. Pfizer, Inc.
  • 16.20. Processa Pharmaceuticals, Inc.
  • 16.21. Sanofi S.A.
  • 16.22. Takeda Pharmaceutical Company Limited
  • 16.23. Theravance Biopharma
  • 16.24. Vanda Pharmaceuticals Inc.
  • 16.25. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROPARESIS DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL GASTROPARESIS DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL GASTROPARESIS DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL GASTROPARESIS DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL GASTROPARESIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DOPAMINE ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DOPAMINE ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DOPAMINE ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CISAPRIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CISAPRIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CISAPRIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DOMPERIDONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DOMPERIDONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DOMPERIDONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL METOCLOPRAMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL METOCLOPRAMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL METOCLOPRAMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MOTILIN RECEPTOR AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MOTILIN RECEPTOR AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MOTILIN RECEPTOR AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AZITHROMYCIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AZITHROMYCIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AZITHROMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ERYTHROMYCIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ERYTHROMYCIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ERYTHROMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SEROTONIN RECEPTOR AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SEROTONIN RECEPTOR AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SEROTONIN RECEPTOR AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GRANISETRON MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GRANISETRON MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONDANSETRON MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONDANSETRON MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONDANSETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIABETIC GASTROPARESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIABETIC GASTROPARESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIABETIC GASTROPARESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IDIOPATHIC GASTROPARESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IDIOPATHIC GASTROPARESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IDIOPATHIC GASTROPARESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POSTSURGICAL GASTROPARESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POSTSURGICAL GASTROPARESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POSTSURGICAL GASTROPARESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. GCC GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 139. GCC GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 140. GCC GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 141. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. GCC GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. G7 GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. G7 GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. G7 GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 166. G7 GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 167. G7 GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 168. G7 GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. G7 GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. G7 GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. NATO GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 175. NATO GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 176. NATO GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 177. NATO GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. NATO GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. NATO GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. NATO GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. CANADA GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 194. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 195. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 196. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. MEXICO GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 203. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 204. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 205. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 212. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 213. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 214. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. GERMANY GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 230. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 231. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 232. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. FRANCE GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 239. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 240. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 241. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 248. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 249. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 250. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. ITALY GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 257. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 258. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 259. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. SPAIN GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 266. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 267. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 268. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. INDIA GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 284. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 285. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 286. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. JAPAN GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 293. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 294. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 295. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 299. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 302. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 303. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 304. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 311. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 312. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 313. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 315. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 317. GLOBAL GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 318. GLOBAL GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025